Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Diabetes and Its Complications|January 3, 2019
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetesYehuda Handelsman, Christina Chovanes, Terry Dex, et al.
Clinical Therapeutics|December 28, 2019
The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector DeviceJuan Pablo Frias, Michael J Koren, Virginie Loizeau, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2Thomas Danne, Steven Edelman, Juan Pablo Frias, et al.
Cell Metabolism|August 3, 2017
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 DiabetesJuan Pablo Frias, Edward J Bastyr, Louis Vignati, et al.
Advances in Therapy|July 31, 2019
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L TrialLawrence Blonde, Timothy S Bailey, Jason Chao, et al.
Diabetes, Obesity & Metabolism|January 28, 2020
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimensJuan Pablo Frias, Michael A Nauck, Joanna Van, et al.
Diabetes, Obesity & Metabolism|April 24, 2020
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trialStefano Del Prato, Juan Pablo Frias, Lawrence Blonde, et al.
Diabetes, Obesity & Metabolism|April 4, 2023
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trialsVanita R Aroda, Juan Pablo Frias, Linong Ji, et al.
Lancet (London, England)|October 9, 2018
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trialJuan Pablo Frias, Michael A Nauck, Joanna Van, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose studyRohit Loomba, Eric J Lawitz, Juan Pablo Frias, et al.
Pageof 3